Cargando…
Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients
BACKGROUND: Grade 3 oral mucositis (OM) is historically observed in >90% of bone marrow transplant patients who received the cyclophosphamide + total body irradiation (CY+TBI) conditioning regimen. It was previously shown that orotopically applied adrenergic vasoconstrictor prevented up to 100% o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907163/ https://www.ncbi.nlm.nih.gov/pubmed/31832233 http://dx.doi.org/10.15761/ICST.1000293 |
_version_ | 1783478493499097088 |
---|---|
author | Graul-Conroy, Amanda Hoover-Regan, Margo DeSantes, Kenneth B Sondel, Paul M Callander, Natalie S Longo, Walter L Fahl, William E |
author_facet | Graul-Conroy, Amanda Hoover-Regan, Margo DeSantes, Kenneth B Sondel, Paul M Callander, Natalie S Longo, Walter L Fahl, William E |
author_sort | Graul-Conroy, Amanda |
collection | PubMed |
description | BACKGROUND: Grade 3 oral mucositis (OM) is historically observed in >90% of bone marrow transplant patients who received the cyclophosphamide + total body irradiation (CY+TBI) conditioning regimen. It was previously shown that orotopically applied adrenergic vasoconstrictor prevented up to 100% of radiation-induced oral mucositis in two preclinical animal models. METHODS: Adrenergic vasoconstrictor (i.e., phenylephrine in an aqueous-alcohol NG11–1 formulation) was orotopically applied to three patients (ages 24–29) who received the CY+TBI conditioning regimen; they were compared to five matched controls who received no orotopical vasoconstrictor. All patients received the CY+TBI conditioning regimen for acute lymphoblastic leukemia within the University of Wisconsin Adult Bone Marrow Transplant Program. Over the seven-day Cy+TBI conditioning regimen, 20 min before each treatment, either radiation or chemotherapy, vasoconstrictor was applied topically to the oral cavity, and patients then received either 1.5 Gy whole-body radiation or IV cyclophosphamide. RESULTS: OM severity was scored over a three-week period using: i) physican assessments, ii) daily photos of the oral cavity, iii) oral pain and oral function score sheets, and iv) recorded narcotic consumption. Both “Grade 3 OM” duration and “any OM” duration in vasoconstrictor-treated patients were substantially lower than for the five control patients. Though nasogastric tube or total parenteral nutrition were used in 3 out of 5 control patients, there was no use of these supportive care measures in the three vasoconstrictor-treated patients. CONCLUSION: Orotopically applied NG11–1 vasoconstrictor formulation substantially reduced the incidence and severity of “Grade 3” and “any” oral mucositis when compared to matched control patients, all of whom received the same CY+TBI conditioning regimen. The liquid orotopical formulation was easily tolerated by patients both in its ease of use and lack of side effects. |
format | Online Article Text |
id | pubmed-6907163 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
record_format | MEDLINE/PubMed |
spelling | pubmed-69071632019-12-12 Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients Graul-Conroy, Amanda Hoover-Regan, Margo DeSantes, Kenneth B Sondel, Paul M Callander, Natalie S Longo, Walter L Fahl, William E Integr Cancer Sci Ther Article BACKGROUND: Grade 3 oral mucositis (OM) is historically observed in >90% of bone marrow transplant patients who received the cyclophosphamide + total body irradiation (CY+TBI) conditioning regimen. It was previously shown that orotopically applied adrenergic vasoconstrictor prevented up to 100% of radiation-induced oral mucositis in two preclinical animal models. METHODS: Adrenergic vasoconstrictor (i.e., phenylephrine in an aqueous-alcohol NG11–1 formulation) was orotopically applied to three patients (ages 24–29) who received the CY+TBI conditioning regimen; they were compared to five matched controls who received no orotopical vasoconstrictor. All patients received the CY+TBI conditioning regimen for acute lymphoblastic leukemia within the University of Wisconsin Adult Bone Marrow Transplant Program. Over the seven-day Cy+TBI conditioning regimen, 20 min before each treatment, either radiation or chemotherapy, vasoconstrictor was applied topically to the oral cavity, and patients then received either 1.5 Gy whole-body radiation or IV cyclophosphamide. RESULTS: OM severity was scored over a three-week period using: i) physican assessments, ii) daily photos of the oral cavity, iii) oral pain and oral function score sheets, and iv) recorded narcotic consumption. Both “Grade 3 OM” duration and “any OM” duration in vasoconstrictor-treated patients were substantially lower than for the five control patients. Though nasogastric tube or total parenteral nutrition were used in 3 out of 5 control patients, there was no use of these supportive care measures in the three vasoconstrictor-treated patients. CONCLUSION: Orotopically applied NG11–1 vasoconstrictor formulation substantially reduced the incidence and severity of “Grade 3” and “any” oral mucositis when compared to matched control patients, all of whom received the same CY+TBI conditioning regimen. The liquid orotopical formulation was easily tolerated by patients both in its ease of use and lack of side effects. 2018-11-29 2018-12 /pmc/articles/PMC6907163/ /pubmed/31832233 http://dx.doi.org/10.15761/ICST.1000293 Text en http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Article Graul-Conroy, Amanda Hoover-Regan, Margo DeSantes, Kenneth B Sondel, Paul M Callander, Natalie S Longo, Walter L Fahl, William E Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients |
title | Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients |
title_full | Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients |
title_fullStr | Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients |
title_full_unstemmed | Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients |
title_short | Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients |
title_sort | reduction in oral mucositis severity using a topical vasoconstrictor: a case report of three bone marrow transplant patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6907163/ https://www.ncbi.nlm.nih.gov/pubmed/31832233 http://dx.doi.org/10.15761/ICST.1000293 |
work_keys_str_mv | AT graulconroyamanda reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients AT hooverreganmargo reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients AT desanteskennethb reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients AT sondelpaulm reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients AT callandernatalies reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients AT longowalterl reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients AT fahlwilliame reductioninoralmucositisseverityusingatopicalvasoconstrictoracasereportofthreebonemarrowtransplantpatients |